Professional Documents
Culture Documents
of
medicine
editorials
1286
www.nejm.org
Downloaded from www.nejm.org on August 6, 2007 . Copyright 2005 Massachusetts Medical Society. All rights reserved.
editorials
patients have characteristic neuropsychological difficulties, including problems in paying attention, learning new information, and recognizing social cues, such as the emotional meaning of facial expressions. Their social isolation, loss of sense of pleasure, inability to make decisions, and poor selfcare forms a third symptom complex. Patients who carry the diagnosis of schizophrenia vary markedly in these various aspects of their illness. Efficacy is therefore difficult to measure. The time to discontinuation of medication for any reason a side effect, poor efficacy, or the patients decision about adherence was the principal outcome variable in CATIE. Its advantage as a primary measure is that it is relatively definable and less subject to the vicissitudes of patients descriptions of their symptoms and the perception of these symptoms by others, even those trained in assessing them. CATIE used a single scale, the Positive and Negative Syndrome Scale (PANSS), to rate patients symptoms as a secondary outcome. Side effects were recognized as an important issue in the design of CATIE. The results could be viewed as discouraging. No drug provided the majority of patients a treatment that lasted the full 18 months of the study. Thus, treating schizophrenia, even with new-generation drugs, is only partially effective and is associated with problematic side effects. Only 36 percent of the patients receiving the most effective drug, olanzapine, completed the trial. Twenty-five percent of those receiving perphenazine completed the trial. Patients receiving other second-generation antipsychotic drugs quetiapine, risperidone, and ziprasidone did no better than those receiving perphenazine. Thus, there was a small improvement with olanzapine as compared with the first-generation drug perphenazine, but this advantage was not observed with the other second-generation drugs. This difference was reflected in the other clinical measurements, including PANSS ratings. The greater efficacy of olanzapine, as compared with that of these other drugs, is consistent with the results of a recent meta-analysis.8 However, olanzapine was also associated with notable metabolic effects. Thirty percent of the patients receiving olanzapine gained more than 7 percent of their body weight during the trials, as compared with 7 to 16 percent of those receiving the other drugs. There were comparable problems revealed in measured blood glucose, cholesterol, triglyceride, and glycosylated hemoglobin levels. Thus, the patient with schizophrenia and his or
her doctor face difficult choices. Two drugs, olanzapine and clozapine, appear to be more effective than other agents. However, both drugs induce a significantly greater number of serious side effects. Even the most feared side effect of first-generation drugs, tardive dyskinesia, seems less troubling than potentially fatal metabolic problems. Does the apparently moderate increase in the efficacy of olanzapine and clozapine justify the use of these agents for treating patients? The answer to this question is a matter of clinical judgment and informed patient preference. Most clinicians offer patients several possibilities over the course of their illness. Few clinicians offer patients first-generation drugs initially because the immediate problems with movement disorder are associated with poor adherence. The relative absence of side effects with risperidone, quetiapine, and ziprasidone make them frequent choices for initial treatment for many patients. However, over the duration of the illness, it is striking that olanzapine and clozapine often result in an increase in cognition that can lead to alterations in its course, although in some patients these improvements occur with other drugs as well.9,10 With these agents, patients resume vocational and social interests that seemed irretrievably lost early in the course of their illness. Heavy cigarette smoking often remits during treatment with olanzapine and clozapine, indicating decreased reliance on the effects of nicotine.11 Because metabolic problems are likely to occur, dietary and exercise counseling should be introduced before the initiation of treatment with these two drugs. Although no one postulates that the biologic effects of clozapine and olanzapine are permanent, the positive effects often persist when, because of metabolic effects, treatment is switched to other second-generation or even first-generation drugs. CATIE does not capture all these clinical points, but it provides data consistent with these clinical observations. It would thus seem reasonable to try olanzapine and clozapine in any patient with schizophrenia who has not had a full clinical remission of the illness, which includes the reversal of cognitive and psychosocial disabilities. However, it is also prudent to switch treatment from these drugs to one of the others if a metabolic syndrome is threatening the patients general health. The problem of which antipsychotic agents to use is particularly poignant for patients with childhood-onset schizophrenia. These young patients, who are often initially referred to pediatricians for
www.nejm.org
1287
Downloaded from www.nejm.org on August 6, 2007 . Copyright 2005 Massachusetts Medical Society. All rights reserved.
The
of
medicine
school problems, begin experiencing hallucinations and delusions before the age of 13 years.12 Olanzapine is frequently the medication that provides optimal remission of their mental symptoms. A child who is less disturbed, despite the nearly inevitable massive weight gain, appears at least at first to have a better outcome. However, as the obesity continues to increase over a period of several years, affected children and families eventually ask to switch to other drugs, to restore normal weight, even at the cost of exacerbated psychosis. Of course, new drugs that do not have metabolic side effects but that do confer the antipsychotic effects of clozapine and olanzapine would be desirable. Just as the second generation of drugs moved beyond D2 antagonism, aripiprazole a partial agonist at dopamine D2 receptors that facilitates low levels of receptor activation while blocking higher levels as well as other new drugs in development have mechanisms that move beyond the dopamine D25-hydroxytryptamine2A hypothesis. How these drugs perform in comparison with olanzapine is still unknown. The value of CATIE is that it provides solid evidence to help clinicians and their patients make the difficult decisions needed to optimize the treatment of schizophrenia with the compounds currently available.
From the Department of Psychiatry, University of Colorado Health Sciences Center, and the Veterans Affairs Medical Center both in Denver.
dicts clinical and pharmacological potencies of antischizophrenic drugs. Science 1976;192:481-3. 2. Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry 1996;153: 321-30. 3. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-96. 4. Meltzer HY. Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology (Berl) 1989;99:Suppl:S18-S27. 5. Sernyak MJ, Leslie DL, Alarcon RD, Losonczy MF, Rosenheck R. Association of diabetes mellitus with use of atypical neuroleptics in the treatment of schizophrenia. Am J Psychiatry 2002;159: 561-6. 6. Lindenmayer JP, Czobor P, Volavka J, et al. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003;160:290-6. 7. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23. 8. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60: 553-64. 9. Bilder RM, Goldman RS, Volavka J, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 2002;159:1018-28. 10. Green MF, Marder SR, Glynn SM, et al. The neurocognitive effects of low-dose haloperidol: a two-year comparison with risperidone. Biol Psychiatry 2002;51:972-8. 11. McEvoy JP, Freudenreich O, Wilson WH. Smoking and therapeutic response to clozapine in patients with schizophrenia. Biol Psychiatry 1999;46:125-9. 12. Schaeffer JL, Ross RG. Childhood-onset schizophrenia: premorbid and prodromal diagnostic and treatment histories. J Am Acad Child Adolesc Psychiatry 2002;41:538-45.
Copyright 2005 Massachusetts Medical Society.
1288
www.nejm.org
Downloaded from www.nejm.org on August 6, 2007 . Copyright 2005 Massachusetts Medical Society. All rights reserved.